Less than a tenth of individuals eligible to benefit from obesity jabs like Wegovy are able to get them, states the WHO as it publishes its first guidance on the medications.
Given in excess of 1,000,000,000 people worldwide currently obese, it is calling for broader and more equitable access to GLP-1 medication.
Based on projections, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"Our new guidelines acknowledges that excess weight is a long-term condition that can be managed with thorough and continuous care," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are key barriers to broad access to the jabs that can assist patients in reducing significant body mass, notes the organization.
Skinny Jab Scarcity
Even under the present most favorable case, the supply of these medications might only reach approximately 100 million people – less than 10% of eligible patients, according to the health organization.
The recommendation calls on governments and firms to expand availability, via strategies like voluntary licensing.
Exclusive production rights on semaglutide – the primary component of the drug Wegovy – is scheduled to end in multiple countries in 2026.
The Way Obesity Jabs Function
These medications replicate a biological compound to slow digestion, suppress the appetite and enhance the sense of being full so people eat less.
Individuals usually see weight reduction within a few weeks of commencing the once-weekly jabs.
Research points to users may put most of the weight back on within a year of discontinuing the medication, as their typical hunger resume.
Being carrying excess weight increases your chance for developing health problems, like diabetes, cardiovascular issues, brain attack, and specific cancers.
Obesity concerns people in every country and was associated with millions of deaths worldwide in 2024, according to the health agency.
